Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEM NASDAQ:ETON NASDAQ:JANX NASDAQ:LFCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$13.70+5.5%$14.47$5.68▼$16.74$797.72M-0.011.12 million shs1.32 million shsETONEton Pharmaceuticals$31.59-1.6%$28.36$13.09▼$35.66$879.57M0.87400,278 shs206,786 shsJANXJanux Therapeutics$13.56-0.7%$14.51$12.12▼$35.34$833.05M2.53889,400 shs860,404 shsLFCRLifecore Biomedical$5.64-0.2%$4.94$3.63▼$8.98$211.93M1.06185,656 shs123,762 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+7.72%-10.05%-19.63%-3.78%+44.54%ETONEton Pharmaceuticals+3.75%+11.11%+8.08%+69.62%+112.79%JANXJanux Therapeutics+3.88%-0.73%-5.20%+0.59%-46.35%LFCRLifecore Biomedical-0.70%-2.42%+23.90%-13.61%-16.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$13.70+5.5%$14.47$5.68▼$16.74$797.72M-0.011.12 million shs1.32 million shsETONEton Pharmaceuticals$31.59-1.6%$28.36$13.09▼$35.66$879.57M0.87400,278 shs206,786 shsJANXJanux Therapeutics$13.56-0.7%$14.51$12.12▼$35.34$833.05M2.53889,400 shs860,404 shsLFCRLifecore Biomedical$5.64-0.2%$4.94$3.63▼$8.98$211.93M1.06185,656 shs123,762 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics+7.72%-10.05%-19.63%-3.78%+44.54%ETONEton Pharmaceuticals+3.75%+11.11%+8.08%+69.62%+112.79%JANXJanux Therapeutics+3.88%-0.73%-5.20%+0.59%-46.35%LFCRLifecore Biomedical-0.70%-2.42%+23.90%-13.61%-16.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 2.63Moderate Buy$32.00133.58% UpsideETONEton Pharmaceuticals 2.40Hold$41.0029.79% UpsideJANXJanux Therapeutics 2.60Moderate Buy$45.85238.10% UpsideLFCRLifecore Biomedical 2.00Hold$6.006.38% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, JANX, ETON, and CGEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.006/8/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.005/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.005/8/2026JANXJanux Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $58.005/7/2026LFCRLifecore Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$6.92 per shareN/AETONEton Pharmaceuticals$79.95M10.82$0.01 per share6,195.02$0.98 per share32.23JANXJanux Therapeutics$10M82.69N/AN/A$15.91 per share0.85LFCRLifecore Biomedical$128.87M1.64N/AN/A$0.42 per share13.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.07N/A16.54N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)JANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)LFCRLifecore BiomedicalN/A-$0.94N/AN/AN/A-25.43%-1,643.15%-14.40%8/5/2026 (Estimated)Latest LFCR, JANX, ETON, and CGEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/6/2026Q1 2026LFCRLifecore Biomedical-$0.29-$0.43-$0.14-$0.43$25.96 million$23.19 million3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million3/16/2026Transition periodLFCRLifecore Biomedical-$0.11-$0.16-$0.05-$0.16$35.31 million$35.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A10.2810.28ETONEton Pharmaceuticals0.621.210.88JANXJanux TherapeuticsN/A17.0117.01LFCRLifecore BiomedicalN/A3.792.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%ETONEton Pharmaceuticals27.86%JANXJanux Therapeutics75.39%LFCRLifecore Biomedical83.36%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics8.60%ETONEton Pharmaceuticals16.49%JANXJanux Therapeutics7.90%LFCRLifecore Biomedical32.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableETONEton Pharmaceuticals2027.39 million22.88 millionOptionableJANXJanux Therapeutics3060.98 million56.17 millionOptionableLFCRLifecore Biomedical69037.51 million25.25 millionOptionableLFCR, JANX, ETON, and CGEM HeadlinesRecent News About These CompaniesLifecore Biomedical (NASDAQ:LFCR) Stock Rating Upgraded by Wall Street ZenJune 6, 2026 | americanbankingnews.comLifecore Biomedical Signs Agreement with New Biopharmaceutical CustomerJune 2, 2026 | globenewswire.comHow The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 ExpectationsMay 29, 2026 | finance.yahoo.comLifecore Biomedical to Participate in William Blair 46th Annual Growth Stock ConferenceMay 21, 2026 | taiwannews.com.twTLifecore Biomedical to Participate in William Blair 46th Annual Growth Stock ConferenceMay 21, 2026 | globenewswire.comLifecore Biomedical to Participate at CDMO Live EuropeMay 12, 2026 | globenewswire.comLifecore Biomedical: Q1 Earnings SnapshotMay 6, 2026 | stamfordadvocate.comSLifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comLifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate UpdateMay 6, 2026 | globenewswire.comLifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026April 29, 2026 | globenewswire.comLaughing Water Capital’s Insights on Lifecore Biomedical (LFCR)April 27, 2026 | insidermonkey.comLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 22, 2026 | globenewswire.comLifecore Biomedical to Participate at 12th Annual American Biomanufacturing SummitApril 8, 2026 | globenewswire.comPomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Lifecore Biomedical, Inc. Securities - LFCRApril 6, 2026 | globenewswire.comLifecore Biomedical Earnings Call Signals Profitable ShiftMarch 28, 2026 | tipranks.comLifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63March 27, 2026 | msn.comLifecore Biomedical, Inc.: Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical CustomerMarch 26, 2026 | finanznachrichten.deLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 26, 2026 | globenewswire.comLifecore Biomedical Inc LFCRMarch 26, 2026 | morningstar.comMLifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical CustomerMarch 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, JANX, ETON, and CGEM Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$13.70 +0.72 (+5.55%) Closing price 04:00 PM EasternExtended Trading$13.34 -0.36 (-2.62%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$31.59 -0.52 (-1.62%) Closing price 04:00 PM EasternExtended Trading$31.57 -0.02 (-0.06%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Janux Therapeutics NASDAQ:JANX$13.56 -0.10 (-0.73%) Closing price 04:00 PM EasternExtended Trading$13.57 +0.01 (+0.10%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Lifecore Biomedical NASDAQ:LFCR$5.64 -0.01 (-0.18%) Closing price 04:00 PM EasternExtended Trading$5.65 +0.01 (+0.18%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
